Clinical data | |
---|---|
Other names | Erbuzole |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H27N3O5S |
Molar mass | 469.56 gยทmol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Erbulozole (R55104) is a congener of the microtubule inhibitor tubulozole. It is undergoing phase I clinical trials as a chemotherapeutic agent.
Synthesis
References
- Van Belle SJ, Distelmans W, Vandebroek J, Bruynseels J, Van Ginckel R, Storme GA (1993). "Phase I trial of erbulozole (R55104)". Anticancer Research. 13 (6B): 2389โ91. PMID 8135472.
Other reading
- Distelmans W, VanGinckel P, Heeres J, Van der Veken LJ (1991). "Erbulozole. Antineoplastic, Microtubule inhibitor". Drugs Future. 16 (6): 577.
Targeted cancer therapy / antineoplastic agents (L01) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CI monoclonal antibodies ("-mab") |
| ||||||||
Tyrosine kinase inhibitors ("-nib") |
| ||||||||
Other |
|
This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |